IM Cannabis Corp IMCC
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
IM Cannabis Announces Form F-3 Resale Registration Statement Filing
-
IM Cannabis Raises US$225,000 of Gross Proceeds in Convertible Note Financing
-
IM Cannabis Corp. Announces First Quarter 2026 Financial Results
-
IM Cannabis Raised US$550,000 of Gross Proceeds in Convertible Note Financings
-
IMC Announces Receipt of Nasdaq Minimum Bid Price Notification
-
IM Cannabis Reports 2025 Results: Revenue of C$54.7 Million with Over 134% Growth in Germany and Positive Operating Cash Flow
Trading Information
- Previous Close Price
- $0.26
- Day Range
- $0.21–0.23
- 52-Week Range
- $0.21–3.75
- Bid/Ask
- $0.21 / $0.21
- Shares Outstanding
- 9.02M
- Market Cap
- $1.96M
- Volume/Avg
- 5M / 4M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 0.03
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
IM Cannabis Corp is a Canada-based international medical cannabis company. It operates in the field of medical cannabis, through Focus Medical Herbs Ltd. (Focus), which holds a cultivation license to breed, grow, and supply medical cannabis products The majority of its revenues are generated from sales of medical cannabis products to customers in Israel. The remaining revenues are generated from sales of medical cannabis, as well as other products, to customers in Germany. Geographically, the majority revenue is generated from Germany, and also has its presence in Israel.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Small Value
- Total Number of Employees
- 44
- Website
- https://www.imcannabis.com
Valuation
|
Metric
|
IMCC
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | 0.03 |
Price/Cash Flow | — |
Price/Earnings
IMCC
Financial Strength
|
Metric
|
IMCC
|
|---|---|
Quick Ratio | 0.29 |
Current Ratio | 0.55 |
Interest Coverage | −3.00 |
Quick Ratio
IMCC
Profitability
|
Metric
|
IMCC
|
|---|---|
Return on Assets (Normalized) | −40.69% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | −74.23% |
Return on Assets
IMCC
Drug Manufacturers - Specialty & Generic Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| ARYx Therapeutics Inc
ARYX
| — | Sjnt | — | |||
| Merck KGaA
MKGAF
| — | Wsqdgpq | $67B | |||
| Merck KGaA ADR
MKKGY
| Dcbsrwjwt | Zqhhrd | $67B | |||
| Galderma Group AG ADR
GALDY
| — | Zndmqz | $51B | |||
| Galderma Group AG Registered Shares
GDERF
| — | Cfgwhv | $51B | |||
| Takeda Pharmaceutical Co Ltd
TKPHF
| — | Llqm | $50B | |||
| Takeda Pharmaceutical Co Ltd ADR
TAK
| — | Fkqwf | $50B | |||
| Jiangsu Hengrui Pharmaceuticals Co Ltd ADR
JHPCY
| — | Ckmwcps | $47B | |||
| Teva Pharmaceutical Industries Ltd ADR
TEVA
| Szqxpdhl | Cgxvdv | $40B | |||
| Teva Pharmaceutical Industries Ltd
TEVJF
| Dkxxvjdp | Dwmnsd | $40B |
United States